CJC-1295 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-10. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
== R == RCM – Rapid Communications in Mass Spectrometry REIMS – Rapid evaporative ionization mass spectrometry REMPI – Resonance enhanced multiphoton ionization RGA – Residual gas analyzer RI – Resonance ionization
A known side effect of bismuth salts is harmless and reversible darkening of tongue and stool by formation of bismuth sulfite. Other side effects of bismuth containing combination therapies are often difficult to assign to a specific component.
== Regulatory scrutiny == In September 2022, Pilot launched a controversial advertising campaign taking aim at R U OK? day. Large billboards with R U OK?'s corporate branding criticised the mental health awareness initiative for making conversation rather than taking action. The campaign received criticism for appearing as a marketing effort disguised as mental health advocacy, with critics noting the company's treatment model focuses on pharmaceutical prescriptions rather than counselling services. In 2023, TV station Seven featured a story about former AFL player and Pilot ambassador Dale Thomas on its news bulletin. Pilot received criticism about the story presenting more like an informercial. ABC TV's Media Watch featured Eucalyptus and Pilot to further highlight the paid partnership and lack of reporting on the upcoming regulator crackdowns. Pilot later turned the news bulletin into an ad on Facebook and Instagram. In 2024, Pilot's TV ad for an erectile dysfunction treatment received 35 complaints for concerns of sexual innuendo to Ad Standards. The Ad Standard Community Panel assessed whether the ad breached the advertising rules and determined no breach. In 2025, the same ad received 32 complaints with the same outcome. In 2025, Pilot received backlash for their Father's Day campaign, which encouraged its Instagram followers to "gift" their father the company's erectile dysfunction treatments instead of a more traditional gift.
Sources: en.wikipedia.org
=== Carrier gas selection and flow rates === Typical carrier gases include helium, nitrogen, argon, and hydrogen. Which gas to use is usually determined by the detector being used, for example, a DID requires helium as the carrier gas. When analyzing gas samples the carrier is also selected based on the sample's matrix, for example, when analyzing a mixture in argon, an argon carrier is preferred because the argon in the sample does not show up on the chromatogram. Safety and availability can also influence carrier selection. The purity of the carrier gas is also frequently determined by the detector, though the level of sensitivity needed can also play a significant role. Typically, purities of 99.995% or higher are used. The most common purity grades required by modern instruments for the majority of sensitivities are 5.0 grades, or 99.999% pure meaning that there is a total of 10 ppm of impurities in the carrier gas that could affect the results. The highest purity grades in common use are 6.0 grades, but the need for detection at very low levels in some forensic and environmental applications has driven the need for carrier gases at 7.0 grade purity and these are now commercially available. Trade names for typical purities include "Zero Grade", "Ultra-High Purity (UHP) Grade", "4.5 Grade" and "5.0 Grade". The carrier gas linear velocity affects the analysis in the same way that temperature does (see above). The higher the linear velocity the faster the analysis, but the lower the separation between analytes.
There are large wealth disparities, and many post-soviet economies are described as oligarchic. Since the dissolution of the Soviet Union, annual polling by the Levada Center has shown that over 50% of Russia's population regretted this event, with the only exception to this being in 2012 when support for the Soviet Union dipped below 50 percent. A 2018 poll showed that 66% of Russians regretted the fall of the Soviet Union, setting a 15-year record, and the majority of these regretting opinions came from people older than 55. In 2020, polls conducted by the Levada Center found that 75% of Russians agreed that the Soviet era was the greatest era in their country's history. According to the New Russia Barometer (NRB) polls by the Centre for the Study of Public Policy, 50% of Russian respondents reported a positive impression of the Soviet Union in 1991. This increased to about 75% of NRB respondents in 2000, dropping slightly to 71% in 2009. Throughout the 2000s, an average of 32% of NRB respondents supported the restoration of the Soviet Union. In a 2021 poll, a record 70% of Russians indicated they had a mostly/very favourable view of Joseph Stalin. In Armenia, 12% of respondents said the USSR collapse did good, while 66% said it did harm. In Kyrgyzstan, 16% of respondents said the collapse of the USSR did good, while 61% said it did harm. In a 2018 Rating Sociological Group poll, 47% of Ukrainian respondents had a positive opinion of Soviet leader Leonid Brezhnev, who ruled the Soviet Union from 1964 to 1982, while viewing Lenin, Stalin, and Gorbachev very negatively.
Coombs test: Negative (rules-out autoimmune hemolytic anemia) Osmotic fragility test: Positive (Spherocytes will rupture in liquid solutions less concentrated than the inside of the red blood cell. This is due to increased permeability of the spherocyte membrane to salt and water, which enters the concentrated inner environment of the RBC and leads to its rupture. The osmotic fragility test is no longer considered the gold standard for diagnosing hereditary spherocytosis, as it misses ~25% of cases). Acidified glycerol lysis test: Positive (A newer version of the osmotic fragility test that adds glycerol to a hypotonic solution. This produces lysis, a positive test, quicker that the traditional saline version). Supportive blood work: Mean cell volume (MCV): Normocytic (normal range: 80–100 fL), or slightly lower. Spherocytes are slightly smaller than normal biconcave red blood cells. Mean corpuscular hemoglobin concentration (MCHC): Increased (normal range: 31–36% Hb/cell). This is secondary to less water being in the cell. MCHC can be normal when HS is combined with iron deficiency anaemia or thalassaemia. Red blood cell distribution width (RDW): Increased (normal range: 11–15%). The spherocytes create variation in the size of the red blood cells on average, thus expanding the distribution. Red blood cell count (RBC): Sometimes increased early (normal range males: 4.3–5.9 million/mm3; normal range females: 3.5–5.5 million/mm3). The loss of surface area per cells cause the body to mass-produce red blood cells. The spleen will filter spherocytes out and change this value.
== Sweetness properties == On a weight basis, brazzein is 500 to 2000 times sweeter than sucrose, compared to 10% sucrose and 2% sucrose solution respectively. Its sweet perception is more similar to sucrose than that of thaumatin, with a clean sweet taste, lingering aftertaste, and slight delay (longer than aspartame) in an equi-sweet solution. Brazzein is stable over a broad pH range from 2.5 to 8, and is heat stable at 98 °C (208 °F) for 2 hours.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.